This paper describes Hokkaido's cancer genomic medicine provision system, including its exit strategy, and the human resource development that serve as its foundation.The third-term Basic Plan to Promote Cancer Control Programs in Japan started in 2018. Preparation of the cancer genomic medicine has been newly demanded in this program. Since 2018, the Cancer Genome Medicine Core Base Hospitals( CGM-CBHs), the Cancer Genome Medicine Base Hospitals(CGM-BHs)and the Cancer Genome Medicine Cooperation Hospitals(CGM-CHs)were appointed by the Ministry of Health, Labour and Welfare in Japan. Among these, the CGM-CBHs(including our Tohoku University Hospital)play a key role, and the preparation of the system of the cancer genomic medicine in the district is pushed forward in cooperation with the CGM-BHs and the CGM-CHs. Although the cancer genomic medicine is constantly advancing, a difference in cancer genomic medicine is getting wide between these cancer genomic medicine affiliated hospitals and other medical institutions. Tohoku University Hospital is pushing forward the spread and enlightenment of the cancer genomic medicine in this district as the center in the Tohoku district. Here, we introduce activity in Tohoku University Hospital as a CGM-CBH.Kyushu University Hospital has been designated as a Core Hospital for Cancer Genomic Medicine since February 2018. Our institution promotes cancer genomic medicine collaborating with 10 Cooperative Hospitals for Cancer Genomic Medicine among Kyushu region. Over 500 solid tumor cases have been examined by cancer genomic profiling tests and the results have been intensively evaluated and discussed in the expert panel meetings. To expand cancer genomic medicine for Kyushu region, we have started a consultation desk for the cancer patients in the local community and began educating programs as cancer genomic medicine seminars for the medical staff of Cooperative Hospitals for Cancer Genomic Medicine. A consultation system has been established to discuss the indication of"Patient requested medical care system". Kyushu University Hospital is now focusing on rare cancer care and medical genetics. Thus close cooperation with cancer genomic medicine and each department has been started. We would like to look back on current progress and issues of cancer genomic medicine in Kyushu University Hospital.In Japan, 2 comprehensive genome profiling(CGP)tests for cancer was covered by national health insurance in June 2019, and cancer genome medicine was introduced at a total of 225 hospitals designated by the Ministry of Health, Labor and Welfare as"core center hospitals for cancer genome medicine(12 hospitals)"," core hospitals for cancer genome medicine (33 hospitals)", and"collaborative hospitals for cancer genome medicine(180 hospitals)". On the other hand, the interpretation of the results of the cancer CGP test must be discussed by an expert panel conducted at the core center hospitals for cancer genome medicine or the core hospitals for cancer genome medicine, and the results must be explained to patients in order to be covered by insurance. In other words, these hospitals are required to review not only their own cases but also those of collaborating hospitals. https://www.selleckchem.com/products/stattic.html In addition, core center hospitals for cancer genome medicine are required to share information and develop human resources with core hospitals and collaborative hospitals for cancer genome medicine. We herein describes the system for providing cancer genome medicine in our hospital as a core center hospital for cancer genome medicine.BRAF mutation is occurred in about 8% of human malignancy, including 40-60% in malignant melanoma, 50% in thyroid papillary cancer, 10% in colorectal cancer, and a few percent of non-small cell lung cancer. Activated mutation of BRAF is mainly p. V600E mutation. BRAF inhibitors were initially developed in malignant melanoma. In a recent few years, BRAF inhibitor-based therapy has been developed also in other cancers such as lung cancer and colorectal cancer. I herein describe the current status of development of new therapeutic strategies for BRAF-mutated cancer, particularly BRAF-targeting therapy.Breastfeeding plays a key role in the development of the baby, in addition to the benefits to the mother and this dyad. Among the possible difficulties in this process, we have ankyloglossia. Some professionals opt for the frenotomy, although the literature is controversial. This paper aims to present how the literature provides subsidies for health professionals' decision and action in the intersection of the themes breastfeeding, ankyloglossia, and frenotomy.
The research on the platforms SciELO and PubMed used the terms "ankyloglossia," "frenotomy," and "lingual frenulum" and the same ones associated with "breastfeeding." A specific inclusion and exclusion criteria were applied and validated by the American Speech-Language-Hearing Association to reduce any bias in the analysis. In the end, 16 papers were included and, by thematic equivalence, divided into two domains association between lingual frenulum alteration and breastfeeding and between frenotomy and breastfeeding.
The literature does not assure that the frenotomy is the "standard conduct" to be adopted in cases of difficulty in breastfeeding and ankyloglossia.
Further studies are needed on the different types of ankyloglossia and their direct influence on the sucking function and lactation difficulties.
Further studies are needed on the different types of ankyloglossia and their direct influence on the sucking function and lactation difficulties.To compare various parameters associated with oral cancer in young and old patients and systematically compile the data on prognosis or outcome of oral cancer in young and old patients that include case series, matched-pair analyses, institutional series, and database reviews.
Though oral cancer is considered a disease of old age, a recent clinical scenario witnesses its increasing incidence among young persons. When compared to old patients, young patients with oral cancer are exposed to the carcinogens for a very petite period of time suggesting underlying pathogenesis to be distinct from that in older individuals. Literature reports several studies about the occurrence of oral cancer in young patients; however, no unanimous opinion exists about its prognosis and treatment outcomes when compared to older patients. Keeping this in mind, we have extensively studied all the possible aspects (location, local and regional recurrence, nodal and distant metastasis, overall survival, etc.) from the English literature and systematically compiled the available data on prognosis or outcomes of oral cancer.